Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

McMaster University

$242,210.00

Designing Highly Porous Drug-Impregnated Polymer Scaffolds Using Pressurized Gas Expanded Liquids for the Treatment of Lung Fibrosis and Wound Infections

EF 2020-21

Résumé
Highly porous materials offer significant advantages in many biomedical applications based on their extremely high surface areas. In particular, for the delivery of drugs with low water solubility, the high surface area provided by highly porous scaffolds offers unique opportunities for enhancing drug loading thus improving the efficacy of drug therapy. However, most strategies used to prepare such scaffolds are extremely slow and/or require the use of solvents or other additives that can cause issues when the material is used in the body. Our knowledge user Ceapro (a Edmonton-based biotechnology company) has recently developed a high-throughput and rapid processing technology called pressurized gas expanded liquids (PGX) that overcomes these challenges in addition to offering exceptional control over both the macroscopic size of the materials generated (from large continuous networks to microscale particles) as well as the size of the internal pores. We have also, in partnership, developed methods to (1) convert these biopolymer networks to hydrogels by post-processing the polymer scaffolds and/or performing gelation and PGX processing simultaneously and (2) load multiple drugs via a simple and residual solvent-free process. In this proposed project, we aim to exploit these advantages to address key challenges in treating lung fibrosis and infected wounds. For lung fibrosis, the potential to create a highly porous microparticle delivery vehicles loaded with drug would improve the efficacy of inhalation-based therapy; in addition, one of the key biopolymers produced by Ceapro (beta- glucan) provides desirable cell targeting effects. For wound healing, the capacity of the scaffolds to absorb exudate and load tunable mixtures of drugs offers benefits for delivering synergistic drug combinations to treat antibiotic-resistant infections. Together, this work will leverage a patented Canand emerging health challenges for Canadians.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
538813-2019
Name nom
Hoare, Todd
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2019
Award amount
242210
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Installment
inst:2 - 4
Partie
3
Nb partie
4
Application title
Designing Highly Porous Drug-Impregnated Polymer Scaffolds Using Pressurized Gas Expanded Liquids for the Treatment of Lung Fibrosis and Wound Infections
Keyword
NSERC
Application summary
Highly porous materials offer significant advantages in many biomedical applications based on their extremely high surface areas. In particular, for the delivery of drugs with low water solubility, the high surface area provided by highly porous scaffolds offers unique opportunities for enhancing drug loading thus improving the efficacy of drug therapy. However, most strategies used to prepare such scaffolds are extremely slow and/or require the use of solvents or other additives that can cause issues when the material is used in the body. Our knowledge user Ceapro (a Edmonton-based biotechnology company) has recently developed a high-throughput and rapid processing technology called pressurized gas expanded liquids (PGX) that overcomes these challenges in addition to offering exceptional control over both the macroscopic size of the materials generated (from large continuous networks to microscale particles) as well as the size of the internal pores. We have also, in partnership, developed methods to (1) convert these biopolymer networks to hydrogels by post-processing the polymer scaffolds and/or performing gelation and PGX processing simultaneously and (2) load multiple drugs via a simple and residual solvent-free process. In this proposed project, we aim to exploit these advantages to address key challenges in treating lung fibrosis and infected wounds. For lung fibrosis, the potential to create a highly porous microparticle delivery vehicles loaded with drug would improve the efficacy of inhalation-based therapy; in addition, one of the key biopolymers produced by Ceapro (beta- glucan) provides desirable cell targeting effects. For wound healing, the capacity of the scaffolds to absorb exudate and load tunable mixtures of drugs offers benefits for delivering synergistic drug combinations to treat antibiotic-resistant infections. Together, this work will leverage a patented Canand emerging health challenges for Canadians.